To explore the role of tumor-infiltrating CD38+ CD8+ T cells in NSCLC and whether they can be used as target cells for immunotherapy, we investigated the prognostic value, functional characteristics and response to anti-PD-1 antibody of CD38+ CD8+ T cell subsets in vitro. This evidence concerns the gene CD38 and non-small cell lung carcinoma.